Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases

References

• Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180–188. doi: 10.1371/journal.pone.0089566
   PubMedGoogle Scholar
• Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of Cannabidiol. Antioxidants (Basel). 2019;9(1):21. doi: 10.3390/antiox9010021
   PubMedGoogle Scholar
• García-Gutiérrez MS, Navarrete F, Gasparyan A, et al. Cannabidiol: a potential new alternative for the treatment of anxiety, depression, and psychotic disorders. Biomolecules. 2020;10(11):1575. doi: 10.3390/biom10111575
   PubMed Web of Science ®Google Scholar
• Commissioner O of the FDA. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy [internet]. FDA. 2020 [cited 2023 Jun 15: Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
   Google Scholar
• Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2022 update: a report from the American heart association. Circulation [internet]. 2022 [cited 2023 Aug 2];145. Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001052
   PubMed Web of Science ®Google Scholar
• Martinez Naya N, Kelly J, Corna G, et al. Molecular and cellular mechanisms of action of Cannabidiol. Molecules. 2023;28(16):5980. doi: 10.3390/molecules28165980
   PubMed Web of Science ®Google Scholar
• Martinez Naya N, Kelly J, Corna G, et al. An overview of Cannabidiol as a multifunctional drug: pharmacokinetics and cellular effects. Molecules. 2024;29(2):473. doi: 10.3390/molecules29020473
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479–1494. doi: 10.1111/j.1476-5381.2010.01166.x
   PubMed Web of Science ®Google Scholar
• Miller M, Koch SE, Veteto A, et al. Role of known transient receptor potential vanilloid channels in modulating cardiac mechanobiology. Front Physiol. 2021;12:734113. doi: 10.3389/fphys.2021.734113
   PubMed Web of Science ®Google Scholar
• Watanabe H, Murakami M, Ohba T, et al. TRP channel and cardiovascular disease. Pharmacol Ther. 2008;118(3):337–351. doi: 10.1016/j.pharmthera.2008.03.008
   PubMed Web of Science ®Google Scholar
• Lang H, Li Q, Yu H, et al. Activation of TRPV1 attenuates high salt-induced cardiac hypertrophy through improvement of mitochondrial function. Br J Pharmacol. 2015;172(23):5548–5558. doi: 10.1111/bph.12987
   PubMed Web of Science ®Google Scholar
• Yan Q, Tang J, Zhang X, et al. Does transient receptor potential vanilloid type 1 alleviate or aggravate pathological myocardial hypertrophy? Front Pharmacol [Internet]. 2021 [cited 2023 Jul 21];12. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2021.681286. 10.3389/fphar.2021.681286
   Web of Science ®Google Scholar
• Horton JS, Buckley CL, Stokes AJ. Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice. Channels (Austin). 2013;7(1):17–22. doi: 10.4161/chan.23006
   PubMed Web of Science ®Google Scholar
• Zhong B, Rubinstein J, Ma S, et al. Genetic ablation of TRPV1 exacerbates pressure overload-induced cardiac hypertrophy. Biomed Pharmacother. 2018;99:261–270. doi: 10.1016/j.biopha.2018.01.065
   PubMed Web of Science ®Google Scholar
• Baranowska-Kuczko M, Kozlowska H, Kloza M, et al. Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities. J Hypertens. 2020;38(5):896. doi: 10.1097/HJH.0000000000002333
   PubMed Web of Science ®Google Scholar
• Kossakowski R, Schlicker E, Toczek M, et al. Cannabidiol affects the Bezold-Jarisch Reflex via TRPV1 and 5-HT3 receptors and has peripheral sympathomimetic effects in spontaneously hypertensive and normotensive rats. Front Pharmacol [Internet]. 2019 [cited 2023 Jan 18];10. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2019.00500. 10.3389/fphar.2019.00500
   PubMed Web of Science ®Google Scholar
• Resstel LBM, Tavares RF, Lisboa SFS, et al. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol. 2009;156(1):181–188. doi: 10.1111/j.1476-5381.2008.00046.x
   PubMed Web of Science ®Google Scholar
• Ramage AG, Villalón CM. 5-hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci. 2008;29(9):472–481. doi: 10.1016/j.tips.2008.06.009
   PubMed Web of Science ®Google Scholar
• Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology. 2008;199(2):223–230. doi: 10.1007/s00213-008-1168-x
   PubMed Web of Science ®Google Scholar
• Mishima K, Hayakawa K, Abe K, et al. Cannabidiol prevents cerebral infarction via a Serotonergic 5-hydroxytryptamine 1A receptor–dependent mechanism. Stroke. 2005;36(5):1071–1076. doi: 10.1161/01.STR.0000163083.59201.34
   PubMed Web of Science ®Google Scholar
• Tyagi S, Gupta P, Saini AS, et al. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2:236–240. doi: 10.4103/2231-4040.90879
   PubMedGoogle Scholar
• Lago-Fernandez A, Zarzo-Arias S, Jagerovic N, et al. Relevance of Peroxisome proliferator activated receptors in multitarget paradigm associated with the endocannabinoid system. Int J Mol Sci. 2021;22(3):1001. doi: 10.3390/ijms22031001
   PubMed Web of Science ®Google Scholar
• Cheang WS, Tian XY, Wong WT, et al. The peroxisome proliferator‐activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol. 2015;172(23):5512–5522. doi: 10.1111/bph.13029
   PubMed Web of Science ®Google Scholar
• O’Sullivan SE, Sun Y, Bennett AJ, et al. Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol. 2009;612(1–3):61–68. doi: 10.1016/j.ejphar.2009.03.010
   PubMed Web of Science ®Google Scholar
• Cao Z, Ye P, Long C, et al. Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats. Pharmacology. 2007;79(3):184–192. doi: 10.1159/000100870
   PubMed Web of Science ®Google Scholar
• Shah K, Seeley S, Schulz C, et al. Calcium channels in the heart: disease states and drugs. Cells. 2022;11(6):943. doi: 10.3390/cells11060943
   PubMed Web of Science ®Google Scholar
• Le Marois M, Ballet V, Sanson C, et al. Cannabidiol inhibits multiple cardiac ion channels and shortens ventricular action potential duration in vitro. Eur J Pharmacol. 2020;886:173542. doi: 10.1016/j.ejphar.2020.173542
   PubMed Web of Science ®Google Scholar
• Fulmer ML, Thewke DP. The endocannabinoid system and heart disease: the role of cannabinoid receptor type 2. Cardiovasc Hematol Disord Drug Targets. 2018;18(1):34–51. doi: 10.2174/1871529X18666180206161457
   PubMedGoogle Scholar
• Montecucco F, Lenglet S, Braunersreuther V, et al. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol. 2009;46(5):612–620. doi: 10.1016/j.yjmcc.2008.12.014
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Hanif A, Yun J, et al. Exploring adenosine receptor ligands: potential role in the treatment of cardiovascular diseases. Molecules. 2017;22(6):917. doi: 10.3390/molecules22060917
   PubMed Web of Science ®Google Scholar
• Ibeas Bih C, Chen T, Nunn AVW, et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12(4):699–730. doi: 10.1007/s13311-015-0377-3
   PubMed Web of Science ®Google Scholar
• Gonca E, Darıcı F. The effect of cannabidiol on Ischemia/Reperfusion-induced ventricular arrhythmias: the role of adenosine A1 receptors. J Cardiovasc Pharmacol Ther. 2015;20(1):76–83. doi: 10.1177/1074248414532013
   PubMed Web of Science ®Google Scholar
• Henein MY, Vancheri S, Longo G, et al. The role of inflammation in cardiovascular disease. Int J Mol Sci. 2022;23(21):12906. doi: 10.3390/ijms232112906
   PubMed Web of Science ®Google Scholar
• O’Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173(12):1899–1910. doi: 10.1111/bph.13497
   PubMed Web of Science ®Google Scholar
• Rogacev KS, Cremers B, Zawada AM, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol. 2012;60(16):1512–1520. doi: 10.1016/j.jacc.2012.07.019
   PubMed Web of Science ®Google Scholar
• Kozela E, Pietr M, Juknat A, et al. Cannabinoids Δ9-tetrahydrocannabinol and cannabidiol differentially inhibit the Lipopolysaccharide-activated NF-κB and interferon-β/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem. 2010;285(3):1616–1626. doi: 10.1074/jbc.M109.069294
   PubMed Web of Science ®Google Scholar
• Peyravian N, Deo S, Daunert S, et al. Cannabidiol as a novel therapeutic for immune modulation. Immunotargets Ther. 2020;9:131–140. doi: 10.2147/ITT.S263690
   PubMed Web of Science ®Google Scholar
• Toldo S, Abbate A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat Rev Cardiol. 2024;21(4):219–237. doi: 10.1038/s41569-023-00946-3
   PubMed Web of Science ®Google Scholar
• Liu C, Ma H, Slitt AL, et al. Inhibitory effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with its modulation of the P2X7 receptor in human monocytes. J Nat Prod. 2020;83(6):2025–2029. doi: 10.1021/acs.jnatprod.0c00138
   PubMed Web of Science ®Google Scholar
• Abbate A, Toldo S, Marchetti C, et al. Interleukin-1 and the Inflammasome as Therapeutic Targets in cardiovascular disease. Circ Res. 2020;126(9):1260–1280. doi: 10.1161/CIRCRESAHA.120.315937
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Bátkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010;56(25):2115–2125. doi: 10.1016/j.jacc.2010.07.033
   PubMed Web of Science ®Google Scholar
• Schieber M, Chandel NS. ROS function in Redox signaling and oxidative stress. Curr Biol. 2014;24(10):R453–R462. doi: 10.1016/j.cub.2014.03.034
   PubMed Web of Science ®Google Scholar
• Sugamura K, Keaney F. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med. 2011;51(5):978. doi: 10.1016/j.freeradbiomed.2011.05.004
   PubMed Web of Science ®Google Scholar
• Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart. 2007;93(8):903–907. doi: 10.1136/hrt.2005.068270
   PubMed Web of Science ®Google Scholar
• Judkins CP, Diep H, Broughton BRS, et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE −/− mice. Am J Physiol Heart Circ Physiol. 2010;298(1):H24–32. doi: 10.1152/ajpheart.00799.2009
   PubMed Web of Science ®Google Scholar
• Borges RS, Batista J, Viana RB, et al. Understanding the molecular aspects of tetrahydrocannabinol and Cannabidiol as antioxidants. Molecules. 2013;18(10):12663–12674. doi: 10.3390/molecules181012663
   PubMed Web of Science ®Google Scholar
• Wang Y, Mukhopadhyay P, Cao Z, et al. Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. Sci Rep. 2017;7(1):12064. doi: 10.1038/s41598-017-10924-8
   PubMedGoogle Scholar
• Fouad AA, Albuali WH, Al-Mulhim AS, et al. Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. Environ Toxicol Pharmacol. 2013;36(2):347–357. doi: 10.1016/j.etap.2013.04.018
   PubMed Web of Science ®Google Scholar
• Damy T, Kirsch M, Khouzami L, et al. Glutathione deficiency in cardiac patients is related to the functional status and structural cardiac abnormalities. PLOS ONE. 2009;4(3):e4871. doi: 10.1371/journal.pone.0004871
   PubMed Web of Science ®Google Scholar
• Sun S, Hu F, Wu J, et al. Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons. Redox Biol. 2017;11:577–585. doi: 10.1016/j.redox.2016.12.029
   PubMed Web of Science ®Google Scholar
• Esposito G, Scuderi C, Savani C, et al. Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. Br J Pharmacol. 2007;151(8):1272–1279. doi: 10.1038/sj.bjp.0707337
   PubMed Web of Science ®Google Scholar
• Sun S, Hu F, Wu J, et al. Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons. Redox Biol. 2016;11:577–585. doi: 10.1016/j.redox.2016.12.029
   PubMed Web of Science ®Google Scholar
• Khodadi E. Platelet function in cardiovascular disease: activation of molecules and activation by molecules. Cardiovasc Toxicol. 2020;20(1):1–10. doi: 10.1007/s12012-019-09555-4
   PubMed Web of Science ®Google Scholar
• Formukong EA, Evans AT, Evans FJ. The inhibitory effects of cannabinoids, the active constituents of cannabis sativa L. on human and rabbit platelet aggregation. J Pharm Pharmacol. 2011;41(10):705–709. doi: 10.1111/j.2042-7158.1989.tb06345.x
   Google Scholar
• Walsh SK, Hepburn CY, Kane KA, et al. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacol. 2010;160(5):1234–1242. doi: 10.1111/j.1476-5381.2010.00755.x
   PubMed Web of Science ®Google Scholar
• Feng Y, Chen F, Yin T, et al. Pharmacologic effects of Cannabidiol on acute reperfused myocardial infarction in rabbits: evaluated with 3.0T cardiac magnetic resonance imaging and histopathology. J Cardiovasc Pharmacol. 2015;66(4):354–363. doi: 10.1097/FJC.0000000000000287
   PubMed Web of Science ®Google Scholar
• Wheal AJ, Cipriano M, Fowler CJ, et al. Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation. J Pharmacol Exp Ther. 2014;351(2):457–466. doi: 10.1124/jpet.114.217125
   PubMed Web of Science ®Google Scholar
• Stanley CP, Hind WH, Tufarelli C, et al. Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc Res. 2015;107(4):568–578. doi: 10.1093/cvr/cvv179
   PubMed Web of Science ®Google Scholar
• Bright TP, Farber MO, Brown DJ, et al. Cardiopulmonary effects of cannabidiol in anesthetized mongrel dogs. Toxicol Appl Pharmacol. 1975;31(3):520–526. doi: 10.1016/0041-008X(75)90275-6
   PubMed Web of Science ®Google Scholar
• McQueen DS, Bond SM, Smith PJW, et al. Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats. Eur J Pharmacol. 2004;491(2–3):181–189. doi: 10.1016/j.ejphar.2004.03.045
   PubMed Web of Science ®Google Scholar
• Alves FHF, Crestani CC, Gomes FV, et al. Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors. Pharmacol Res. 2010;62(3):228–236. doi: 10.1016/j.phrs.2010.05.003
   PubMed Web of Science ®Google Scholar
• Granjeiro ÉM, Gomes FV, Guimarães FS, et al. Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. Pharmacol Biochem Behav. 2011;99(4):743–748. doi: 10.1016/j.pbb.2011.06.027
   PubMed Web of Science ®Google Scholar
• Resstel LBM, Joca SRL, Moreira FA, et al. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res. 2006;172(2):294–298. doi: 10.1016/j.bbr.2006.05.016
   PubMed Web of Science ®Google Scholar
• Sultan SR, Millar SA, England TJ, et al. A Systematic Review and meta-analysis of the haemodynamic effects of Cannabidiol. Front Pharmacol [Internet]. 2017 [cited 2023 Feb 1];8. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2017.00081. 10.3389/fphar.2017.00081
   PubMed Web of Science ®Google Scholar
• Jadoon KA, Tan GD, O’Sullivan SE. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight. 2017;2(12):e93760. doi: 10.1172/jci.insight.93760
   PubMed Web of Science ®Google Scholar
• Kumric M, Bozic J, Dujic G, et al. Chronic effects of effective oral cannabidiol delivery on 24-h ambulatory blood pressure and vascular outcomes in treated and untreated hypertension (HYPER-H21-4): study protocol for a randomized, placebo-controlled, and crossover study. J Pers Med. 2022;12(7):1037. doi: 10.3390/jpm12071037
   PubMed Web of Science ®Google Scholar
• Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy. Circ Res. 2018;122(4):624–638. doi: 10.1161/CIRCRESAHA.117.311586
   PubMed Web of Science ®Google Scholar
• Rajesh M, Mukhopadhyay P, Bátkai S, et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol. 2007;293(1):H610–H619. doi: 10.1152/ajpheart.00236.2007
   PubMed Web of Science ®Google Scholar
• Weiss L, Zeira M, Reich S, et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology. 2008;54(1):244–249. doi: 10.1016/j.neuropharm.2007.06.029
   PubMed Web of Science ®Google Scholar
• Sagar S, Liu PP, Cooper LT. Myocarditis. Lancet. 2012;379(9817):738–747. doi: 10.1016/S0140-6736(11)60648-X
   PubMed Web of Science ®Google Scholar
• Lv H, Havari E, Pinto S, et al. Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans. J Clin Invest. 2011;121(4):1561–1573. doi: 10.1172/JCI44583
   PubMed Web of Science ®Google Scholar
• Lee W-S, Erdelyi K, Matyas C, et al. Cannabidiol Limits T Cell–mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. Mol Med. 2016;22(1):136–146. doi: 10.2119/molmed.2016.00007
   PubMedGoogle Scholar
• Park WJ, Oh JG. SERCA2a: a prime target for modulation of cardiac contractility during heart failure. BMB Rep. 2013;46(5):237–243. doi: 10.5483/BMBRep.2013.46.5.077
   PubMed Web of Science ®Google Scholar
• Cardiol Therapeutics Inc. Impact of CardiolRx on myocardial recovery in acute myocarditis. A double-blind, placebo-controlled trial [internet]. clinicaltrials.gov. 2023 [cited 2022 Dec 31]. Available from: https://clinicaltrials.gov/study/NCT05180240
   Google Scholar
• Cardiol Therapeutics Inc. Impact of CardiolRxTM on recurrent pericarditis an open label pilot study [Internet]. clinicaltrials.gov. 2023 [cited 2022 Dec 31]. Available from: https://clinicaltrials.gov/study/NCT05494788
   Google Scholar
• Martinez Naya N. Protective effects of cannabidiol in a mouse model of acute pericarditis. Circ Res. e169–e190.
   Web of Science ®Google Scholar
• Singal PK, Iliskovic N. Doxorubicin-Induced Cardiomyopathy. N Engl J Med. 1998;339(13):900–905. doi: 10.1056/NEJM199809243391307
   PubMed Web of Science ®Google Scholar
• Mauro AG, Mezzaroma E, Toldo S, et al. NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful. Transl Res. 2023;252:9–20. doi: 10.1016/j.trsl.2022.08.004
   PubMed Web of Science ®Google Scholar
• Hao E, Mukhopadhyay P, Cao Z, et al. Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol Med. 2015;21(1):38–45. doi: 10.2119/molmed.2014.00261
   PubMedGoogle Scholar
• Massi P, Solinas M, Cinquina V, et al. Cannabidiol as potential anticancer drug. Brit J Clinical Pharma. 2013;75(2):303–312. doi: 10.1111/j.1365-2125.2012.04298.x
   PubMed Web of Science ®Google Scholar
• Ahmedzai S, Carlyle DL, Calder IT, et al. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer. 1983;48(5):657–663. doi: 10.1038/bjc.1983.247
   PubMed Web of Science ®Google Scholar
• Kalogeris T, Baines CP, Krenz M, et al. Chapter six - cell biology of Ischemia/Reperfusion injury. In: Jeon KW, editor. International Review of Cell and molecular biology [internet]. Academic Press; 2012 [cited 2023 Oct 31]. p. 229–317. Available from: https://www.sciencedirect.com/science/article/pii/B9780123943095000067
   Google Scholar
• Durst R, Danenberg H, Gallily R, et al. Cannabidiol, a nonpsychoactive cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;293(6):H3602–H3607. doi: 10.1152/ajpheart.00098.2007
   PubMed Web of Science ®Google Scholar
• Franco‐Vadillo A, Toledo‐Blass M, Rivera‐Herrera Z, et al. Cannabidiol‐mediated RISK PI3K/AKT and MAPK/ERK pathways decreasing reperfusion myocardial damage. Pharmacol Res Perspect. 2021;9(4):e00784. doi: 10.1002/prp2.784
   PubMed Web of Science ®Google Scholar
• Bouchard J-F, Lépicier P, Lamontagne D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci. 2003;72(16):1859–1870. doi: 10.1016/S0024-3205(02)02474-8
   PubMed Web of Science ®Google Scholar
• Hayakawa K, Mishima K, Fujiwara M. Therapeutic potential of non-psychotropic cannabidiol in ischemic stroke. Pharmaceuticals. 2010;3(7):2197–2212. doi: 10.3390/ph3072197
   Google Scholar
• Lafuente H, Alvarez FJ, Pazos MR, et al. Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs. Pediatr Res. 2011;70(3):272–277. doi: 10.1203/PDR.0b013e3182276b11
   PubMed Web of Science ®Google Scholar
• Logue SE, Gustafsson ÅB, Samali A, et al. Ischemia/Reperfusion injury at the intersection with cell death. J Mol Cell Cardiol. 2005;38(1):21–33. doi: 10.1016/j.yjmcc.2004.11.009
   PubMed Web of Science ®Google Scholar
• Krylatov AV, Ugdyzhekova DS, Bernatskaya NA, et al. Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med. 2001;131(6):523–525. doi: 10.1023/A:1012381914518
   PubMed Web of Science ®Google Scholar
• Zhong B, Wang DH. Protease-activated receptor 2-mediated protection of myocardial ischemia-reperfusion injury: role of transient receptor potential vanilloid receptors. Am J Physiol Regul Integr Comp Physiol. 2009;297(6):R1681–R1690. doi: 10.1152/ajpregu.90746.2008
   PubMed Web of Science ®Google Scholar
• Topal L, Naveed M, Orvos P, et al. The electrophysiological effects of cannabidiol on action potentials and transmembrane potassium currents in rabbit and dog cardiac ventricular preparations. Arch Toxicol. 2021;95(7):2497–2505. doi: 10.1007/s00204-021-03086-0
   PubMed Web of Science ®Google Scholar
• Fu J-D, Laurita KR. Repolarization reserve and action potential dynamics in failing myocytes. Circ Arrhythm Electrophysiol. 2018;11(2):e006137. doi: 10.1161/CIRCEP.118.006137
   PubMed Web of Science ®Google Scholar
• Kicman A, Toczek M. The effects of Cannabidiol, a non-intoxicating compound of cannabis, on the cardiovascular system in health and disease. Int J Mol Sci. 2020;21(18):6740. doi: 10.3390/ijms21186740
   PubMed Web of Science ®Google Scholar
• Sellers EM, Schoedel K, Bartlett C, et al. A multiple-dose, randomized, double-blind, placebo-controlled, parallel-group QT/QTc study to evaluate the electrophysiologic effects of THC/CBD spray. Clinical Pharm Drug Dev. 2013;2(3):285–294. doi: 10.1002/cpdd.36
   PubMed Web of Science ®Google Scholar